Research goal

Anxiety & Stress

Q: Which peptides are researched for anxiety?

The most studied peptides for anxiety are Selank and Semax, both developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and backed by Russian clinical research. Selank is a synthetic analogue of the immunomodulatory peptide tuftsin and has demonstrated anxiolytic effects in multiple human studies, operating via GABAergic modulation and BDNF upregulation without the sedation or dependence risks of benzodiazepines. Semax, derived from ACTH(4-7), has nootropic and mild anxiolytic properties via BDNF and serotonergic pathways. BPC-157 has been studied for stress resilience and anxiety-like behaviour in animal models through dopaminergic and serotonergic modulation. DSIP (Delta Sleep-Inducing Peptide) has stress-normalising properties studied in the context of stress responses and sleep dysregulation. Oxytocin has well-documented anxiolytic effects via limbic system modulation. None of these compounds are FDA-approved as anxiolytics.

Q: How does Selank compare to benzodiazepines for anxiety?

Selank and benzodiazepines both act on GABAergic signalling, but through different mechanisms. Benzodiazepines are positive allosteric modulators of GABA-A receptors, producing sedation, muscle relaxation, and anxiolysis with significant risks of tolerance, dependence, and cognitive impairment. Selank modulates GABAergic tone through a mechanism that does not directly bind the benzodiazepine binding site on GABA-A, and research has not shown the same dependence or withdrawal profile. Selank also upregulates BDNF and affects serotonin metabolism in ways that benzodiazepines do not. Russian clinical studies have reported anxiolytic effects for Selank comparable to some reference anxiolytics, without significant sedation. However, Selank has not been evaluated in large-scale Western randomised controlled trials and is not approved by the FDA or EMA. Its clinical evidence base, while substantial compared to most research peptides, does not match the decades of pharmacological data behind approved anxiolytics.

Q: Can BPC-157 help with stress and anxiety?

BPC-157 has been studied in animal models for its effects on stress-induced behaviour, dopaminergic pathways, and serotonin system modulation. Research has shown that BPC-157 can counteract stress-induced gastrointestinal dysfunction and anxiety-like behaviour in rodent models, and has demonstrated interactions with the dopamine system relevant to stress responses. BPC-157 also modulates nitric oxide pathways and has anti-inflammatory properties that may address physiological stress responses at the systems level. The research is primarily preclinical: large-scale human clinical trials for BPC-157 in anxiety or stress disorders do not exist. BPC-157 is not FDA-approved for any indication. Its relevance to anxiety and stress is mechanistically plausible but requires human clinical validation that has not yet been completed.

Q: What is the evidence level for peptides in anxiety research?

Evidence levels vary considerably across the compounds in this category. Selank has the strongest human clinical evidence, with multiple published Russian clinical trials showing anxiolytic effects, including head-to-head comparisons with reference anxiolytics, in patients with generalised anxiety disorder and neurotic conditions. Oxytocin has extensive human research demonstrating anxiolytic effects via limbic modulation, though primarily in laboratory settings rather than clinical anxiety disorder treatment. Semax has human studies primarily focused on neurological and cognitive applications, with anxiety-relevant secondary findings. BPC-157 and DSIP have primarily preclinical (animal model) evidence for anxiety-relevant outcomes. Cerebrolysin has clinical research in cognitive and neurological contexts with stress-relevant mechanisms. None of these compounds have completed FDA approval trials for anxiety indications. Selank is approved in Russia as an anxiolytic drug; the others are not approved as anxiety treatments in any major jurisdiction.

Q: Are peptides safe to use alongside anxiety medications?

Combining peptides with prescription anxiety medications is a clinical decision that should only be made with a qualified physician. Several compounds in this category interact with the same neurotransmitter systems as established anxiolytics. Selank affects GABA signalling and serotonin metabolism, creating potential for additive sedation or interaction with SSRIs, SNRIs, and benzodiazepines. Semax affects serotonin and BDNF pathways, relevant to interactions with antidepressants. Oxytocin affects limbic circuits modulated by many psychiatric medications. BPC-157 affects dopamine and serotonin systems. DSIP affects sleep and stress hormones that are also targets of some anxiolytics and antidepressants. The absence of systematic interaction studies for these peptides means that potential combinations carry pharmacological risks that have not been characterised in controlled research. This page is an educational research reference and does not constitute medical advice. Do not alter anxiety medication regimens without physician guidance.

Research overview of peptides investigated for anxiety reduction and stress resilience, covering GABAergic, serotonergic, neurotrophic, and limbic mechanisms. No compound on this page is FDA-approved as an anxiolytic. Content is an educational research reference only.

Relevant Compounds

Compound	Class	Primary mechanism	Relevance to anxiety	Link
Selank	Tuftsin analogue / anxiolytic peptide	GABAergic modulation; BDNF upregulation; serotonin metabolism; enkephalin breakdown inhibition	Anxiolysis without sedation or dependence; human clinical trial evidence	View profile →
Semax	ACTH(4-7) analogue / neuropeptide	BDNF and NGF upregulation; serotonergic activity; dopaminergic modulation; neuroprotection	Mild anxiolytic, primarily nootropic; stress resilience via BDNF	View profile →
BPC-157	Pentadecapeptide / cytoprotective	Dopaminergic and serotonergic modulation; nitric oxide pathway; anti-inflammatory; angiogenic	Stress-induced behaviour modulation; GI-stress axis; primarily preclinical evidence	View profile →
Oxytocin	Nonapeptide / neuropeptide hormone	Limbic system modulation; HPA axis dampening; amygdala reactivity reduction; social bonding circuits	Anxiolytic via social and limbic mechanisms; established human research	View profile →
DSIP	Delta sleep-inducing peptide / neuropeptide	Stress hormone normalisation; ACTH and cortisol modulation; sleep architecture support	HPA axis stress normalisation; anxiety via sleep deprivation reduction	View profile →
Cerebrolysin	Neuropeptide mixture / neurotrophic	Multimodal neurotrophic support; BDNF, NGF, and GDNF-like activity; neuroprotection; neuroplasticity	Neural resilience and neuroplasticity relevant to chronic stress; cognitive stress effects	View profile →
Epitalon	Tetrapeptide / pineal bioregulator	Telomerase activation; pineal normalisation; antioxidant; gene expression modulation	Longevity and cellular renewal context; indirect relevance via pineal and sleep regulation	View profile →

Research Context

Anxiety and stress represent one of the most common areas of interest in peptide research, and also one of the most heterogeneous, because "anxiety" encompasses both acute situational stress responses and chronic neurobiological dysregulation of the type seen in generalised anxiety disorder, PTSD, social anxiety disorder, and panic disorder. These conditions involve different, though overlapping, neurobiological substrates: GABAergic inhibitory tone, serotonin and dopamine system balance, HPA (hypothalamic-pituitary-adrenal) axis regulation, limbic system reactivity, and neurotrophic factor expression. The peptides researched in this context operate across these different mechanisms, which means their relevance varies depending on the type and nature of the anxiety being studied.

Selank stands apart from other compounds on this page in having the most developed clinical evidence base. It was approved in Russia as an anxiolytic peptide drug, and multiple published clinical studies have investigated its effects in patients with generalised anxiety and related conditions, including comparisons to reference anxiolytics such as phenibut and some benzodiazepines. Selank operates on GABAergic signalling without directly binding the benzodiazepine site, which is the proposed basis for its anxiolytic profile without the sedation, tolerance, and dependence associated with benzodiazepine class drugs. Selank also inhibits the breakdown of met-enkephalin (an endogenous opioid with anxiolytic properties) and upregulates BDNF, both mechanisms that support longer-term anxiolytic and mood-stabilising effects beyond direct GABA modulation.

Semax, the other major Russian neuropeptide with anxiety-relevant research, is primarily characterised as a nootropic with secondary anxiolytic properties. Its mechanism involves BDNF and NGF upregulation, serotonin system modulation, and dopaminergic effects that collectively produce cognitive enhancement alongside mild stress-attenuation. Semax research has investigated its effects in neurological conditions including ischaemic stroke and cognitive disorders, with anxiety-relevant outcomes observed as secondary findings. It is registered in Russia and Ukraine for neurological indications but is not an approved anxiolytic in Western jurisdictions.

Oxytocin occupies a unique position in this category because its anxiolytic properties are among the best characterised of any neuropeptide, with substantial human research demonstrating amygdala reactivity reduction, HPA axis dampening, and prosocial anxiety reduction via nasal administration. The anxiolytic effects of oxytocin are primarily mediated through limbic circuit modulation, particularly the amygdala and hippocampus, which are central nodes in the fear and anxiety processing circuitry. However, oxytocin's anxiolytic effects are context-dependent: research has shown that it can paradoxically amplify in-group/out-group distinctions in social contexts, and it is not universally anxiolytic across all anxiety subtypes. Oxytocin is not approved for anxiety treatment; it is approved for obstetric indications.

DSIP and Cerebrolysin reach the anxiety context through different routes. DSIP affects HPA axis function and stress hormone regulation, and has been studied in contexts of chronic stress and sleep dysregulation, where its stress-normalising properties address the bidirectional relationship between poor sleep and anxiety amplification. Cerebrolysin provides multimodal neurotrophic support that may build neural resilience against the structural changes that chronic stress induces in the prefrontal cortex and hippocampus, particularly dendritic regression and volume loss in these areas, which underlie impaired emotional regulation in chronic stress states.

Key Research Mechanisms

GABAergic Modulation

GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the central nervous system, and reduced GABAergic tone is a core neurobiological feature of anxiety. Benzodiazepines act as positive allosteric modulators of GABA-A receptors and are the most widely used pharmacological anxiolytics, but carry risks of sedation, cognitive impairment, tolerance, and physical dependence. Selank's proposed mechanism involves modulation of GABAergic signalling without direct binding to the benzodiazepine receptor site, which may account for its reported anxiolytic effect without the characteristic benzodiazepine side-effect profile. The precise molecular target of Selank's GABAergic interaction remains an area of ongoing characterisation. Phenibut, while not a peptide, is another GABAergic compound from the same Russian research tradition, and Selank comparisons to phenibut provide some context for its GABAergic mechanism within that research literature.

Serotonergic & Dopaminergic Pathways

The serotonin system is the primary target of most approved modern anxiolytics and antidepressants, including SSRIs and SNRIs. Both Selank and Semax affect serotonin metabolism: Selank by inhibiting the enzymes responsible for breaking down serotonin and enkephalins, and Semax through direct effects on serotonin receptor expression and turnover. BPC-157 modulates both serotonin and dopamine systems, particularly relevant to its ability to counteract dopamine-depletion states and stress-induced dopaminergic dysregulation. Dopaminergic tone in the prefrontal cortex is critical for executive control of emotional responses, and stress-induced depletion of prefrontal dopamine contributes to impaired top-down regulation of amygdala-driven anxiety responses. Peptides that support dopaminergic signalling in the prefrontal cortex may therefore indirectly support anxiety regulation through enhanced cognitive control mechanisms.

HPA Axis & Cortisol Regulation

The hypothalamic-pituitary-adrenal (HPA) axis governs the physiological stress response via corticotropin-releasing hormone (CRH), ACTH, and cortisol. Chronic HPA axis hyperactivation is a hallmark of chronic stress and anxiety disorders, including PTSD and generalised anxiety disorder. DSIP has been studied for its effects on ACTH and cortisol regulation, normalising stress hormone dysregulation. Oxytocin reduces HPA axis reactivity, lowering cortisol responses to social stressors in laboratory settings. Semax, derived from ACTH(4-7), has complex effects on ACTH-related signalling that include cognitive and potentially HPA-modulating properties, though its primary characterisation is as a nootropic rather than a HPA-targeting compound. Peptides that reduce chronic HPA activation may attenuate the downstream effects of cortisol hypersecretion, including hippocampal volume loss, impaired neurogenesis, and impaired memory consolidation, all of which are observed in chronic anxiety states.

BDNF, Neuroplasticity & Stress Resilience

Brain-derived neurotrophic factor (BDNF) supports neuronal survival, synaptic plasticity, and neurogenesis, particularly in the hippocampus and prefrontal cortex, regions that are structurally affected by chronic stress and anxiety. Reduced BDNF expression is a consistent finding in chronic anxiety and depression, and BDNF upregulation is one of the proposed mechanisms of action of established antidepressants and exercise-based interventions. Both Selank and Semax have demonstrated BDNF upregulation in research models. Cerebrolysin provides neurotrophic support via multiple growth factor analogues including BDNF, NGF, and GDNF, building neural resilience that may protect against the structural consequences of chronic stress. This neurotrophic dimension of peptide anxiolytic research is mechanistically distinct from direct receptor-level modulation and represents a potential long-term stress resilience mechanism rather than acute anxiolysis.

Limbic System & Amygdala Reactivity

The amygdala is the central processing node for fear and threat detection, and its hyperreactivity underlies the heightened threat sensitivity seen across anxiety disorders. Oxytocin has the most direct evidence for amygdala reactivity reduction: intranasal oxytocin has been shown in neuroimaging studies to reduce amygdala responses to threatening social stimuli. BPC-157 has been studied in the context of limbic-related behaviours and dopaminergic pathways that regulate amygdala function. The gut-brain axis is also relevant here: BPC-157 has been studied for its effects on vagal tone and enteric nervous system function, and the bidirectional gut-brain communication pathway is increasingly recognised as a contributor to anxiety regulation. Stress-induced gut dysfunction amplifies anxiety signals through vagal afferent pathways, and compounds that reduce gut inflammation and restore enteric function may have upstream effects on anxiety via the gut-brain axis.

Compound Notes

Selank

Selank (TP-7) is a synthetic heptapeptide analogue of the endogenous immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is registered in Russia as a peptide anxiolytic and is available as nasal drops. Its GABAergic, serotonergic, and enkephalinase-inhibitory mechanisms produce anxiolytic effects in clinical research without the sedation, tolerance, or dependence risks associated with benzodiazepines. Published studies have compared Selank to reference anxiolytics in patients with generalised anxiety disorder and related conditions, reporting comparable efficacy with a favourable tolerability profile. Selank also upregulates BDNF, providing a neurotrophic dimension alongside its acute anxiolytic mechanism. It is not approved in the US, EU, or UK and is not available through licensed pharmacies in these jurisdictions.

Semax

Semax is a synthetic heptapeptide derived from ACTH(4-7) with an added proline-glycine-proline tail for stability. It was developed at the same Russian research institute as Selank and is registered in Russia and Ukraine for neurological indications including ischaemic stroke, traumatic brain injury, and cognitive impairment. Its primary research characterisation is as a nootropic, with anxiolytic effects observed as secondary findings in some studies. Semax upregulates BDNF and NGF, modulates serotonin metabolism, and has dopaminergic activity. For stress and anxiety contexts, its relevance is primarily through stress resilience and BDNF-mediated neuroplasticity rather than as a direct anxiolytic of the Selank type. It is available as nasal drops in Russia and as a subcutaneous research peptide in other jurisdictions.

BPC-157

BPC-157 has a substantial preclinical research base showing effects on dopamine and serotonin systems relevant to stress responses, as well as studies showing attenuation of stress-induced gastrointestinal dysfunction. Its anti-inflammatory and angiogenic properties may address physical manifestations of chronic stress that amplify anxiety through the gut-brain axis. BPC-157 has also been studied in animal models of PTSD-like behaviour and social stress. However, human clinical trial data for BPC-157 in anxiety or stress disorders does not yet exist. BPC-157 is not approved for any indication by the FDA or EMA. Its anxiety-relevance is mechanistically supported but requires human clinical validation.

Oxytocin

Oxytocin is a naturally occurring nonapeptide produced in the hypothalamus with established roles in social bonding, trust, and prosocial behaviour. Its anxiolytic properties are among the most extensively documented of any peptide in human neuroscience research, primarily through nasal administration studies showing amygdala reactivity reduction and HPA axis dampening. Intranasal oxytocin reduces cortisol responses to social stressors and increases feelings of social safety. It is approved for obstetric use (labour induction, uterine atony) but not for anxiety. Research into oxytocin as an anxiolytic is complicated by its context-specificity: its effects are sensitive to the social context of administration and can vary in direction depending on individual differences, attachment style, and the specific anxiety subtype.

DSIP

Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide originally isolated from rabbit thalamus based on its ability to induce slow-wave sleep. Beyond sleep, DSIP has been studied for its effects on the HPA axis, normalising ACTH and cortisol secretion in stress-disrupted patterns. Chronic stress elevates and dysregulates cortisol secretion, contributing to sleep disruption, impaired hippocampal neurogenesis, and anxiety amplification through a vicious cycle. DSIP may interrupt this cycle through both direct sleep architecture effects and HPA axis normalisation. Its research base is primarily from older European and Russian literature; it has not been studied in recent large-scale RCTs. DSIP is not approved for any indication in major jurisdictions.

Cerebrolysin

Cerebrolysin is a mixture of neuropeptides and amino acids derived from porcine brain tissue, providing neurotrophic support through compounds with BDNF, NGF, and GDNF-like activity. Its primary research applications are in Alzheimer's disease, vascular dementia, traumatic brain injury, and stroke recovery. Its relevance to anxiety and stress is primarily through the neurotrophic resilience mechanism: chronic stress induces dendritic regression and volume loss in the prefrontal cortex and hippocampus, which impairs the top-down emotional regulation capacity of these regions. Cerebrolysin's neurotrophic support may counteract these stress-induced structural changes, supporting neural resilience rather than providing direct anxiolysis. It is administered intravenously and is approved in some European and Asian countries for neurological indications, but is not FDA-approved.

Epitalon

Epitalon is a synthetic tetrapeptide derived from the pineal gland bioregulator Epithalamin, studied for telomerase activation and age-related decline in pineal function. Its relevance to anxiety and stress is indirect: pineal gland function governs circadian rhythm and melatonin secretion, and disruption of circadian regulation amplifies HPA axis reactivity and anxiety vulnerability. Epitalon normalises pineal function and has antioxidant properties that may reduce oxidative stress contributions to anxiety pathophysiology. Direct anxiolytic evidence for Epitalon is limited, and it is primarily included in this research context for its pineal and chronobiological mechanisms rather than direct GABAergic or serotonergic anxiety-relevant effects.

Regulatory Note

No peptide discussed on this page is FDA-approved for anxiety, stress, or any psychiatric indication (except oxytocin for obstetric use). Selank is approved in Russia as an anxiolytic peptide drug; other compounds on this page are not approved for anxiety treatment in any major Western jurisdiction. Anyone experiencing anxiety disorders should seek care from a qualified psychiatrist, psychologist, or physician. Combining peptides with prescription psychiatric medications, including SSRIs, SNRIs, benzodiazepines, or other anxiolytics, carries uncharacterised interaction risks and should only be done under physician supervision. This page is an educational research reference and does not constitute medical advice.

Frequently Asked Questions

Which peptides are researched for anxiety?

The most studied peptides for anxiety are Selank, which has clinical trial evidence from Russia as a GABAergic anxiolytic, and Semax, which has mild anxiolytic properties via BDNF and serotonergic mechanisms. Oxytocin has well-documented limbic anxiolytic effects in human research. BPC-157 and DSIP have primarily preclinical evidence for stress and anxiety-relevant outcomes. None are FDA-approved anxiolytics.

How does Selank compare to benzodiazepines for anxiety?

Selank modulates GABAergic tone through a mechanism distinct from benzodiazepine receptor binding, and research has not shown the sedation, tolerance, or dependence profile associated with benzodiazepines. Russian clinical studies report anxiolytic effects comparable to some reference anxiolytics without significant sedation. However, Selank lacks the large-scale Western RCT evidence base that approved anxiolytics carry, and is not approved in the US, EU, or UK. It should not be viewed as a substitute for established anxiety treatment without physician guidance.

Can BPC-157 help with stress and anxiety?

BPC-157 has preclinical evidence showing attenuation of stress-induced behaviour and modulation of dopaminergic and serotonergic pathways relevant to anxiety. It has also been studied for gut-brain axis effects that may reduce anxiety amplification through the vagal pathway. Human clinical trial data in anxiety or stress populations does not yet exist. BPC-157 is not approved for any indication. Its relevance to anxiety is mechanistically plausible but requires human clinical validation.

What is the evidence level for peptides in anxiety research?

Evidence levels vary considerably. Selank has the strongest human clinical evidence with multiple published Russian clinical trials in anxiety patients. Oxytocin has extensive human neuroscience research in laboratory anxiety settings. Semax has human studies primarily in neurological indications with anxiety-relevant secondary findings. BPC-157, DSIP, and Cerebrolysin have primarily preclinical evidence for anxiety-relevant mechanisms. None have completed FDA approval trials for anxiety indications.

Are peptides safe to use alongside anxiety medications?

Combining peptides with prescription anxiety medications, including SSRIs, SNRIs, and benzodiazepines, is a clinical decision that should only be made with a physician. Several compounds on this page interact with the same neurotransmitter systems (GABA, serotonin, dopamine) as established anxiolytics, and systematic drug interaction studies for these peptides do not exist. Potential combinations carry pharmacological risks that have not been characterised in controlled research. Do not alter anxiety medication regimens without physician supervision.